DAIC

JUNE 4, 2024

To improve outcomes and be in compliance with new regulations, it's crucial to better identify and address these issues during the recovery period. I had had a heart attack previously. Stroke recovery is a challenging process that extends for months after hospital discharge.

Stroke 115

Stroke Strokes Innovation Research 115

CardiacWire

MARCH 24, 2024

Wegovy’s recent FDA approval expansion for CVD events and last week’s Medicare Part D policy expansion both come in response to the SELECT trial , which found that Wegovy slashed patients’ major cardiac event risks by 20% over five years, while cutting non-fatal heart attacks by 28% and reducing cardiovascular mortality by 15%.

Medicare 59

Medicare Obesity CMS Medicaid 59

DAIC

MARCH 7, 2024

Patients treated with CardiAMP cell therapy saw an almost 5% lower rate of heart death equivalents at up to two years compared to control patients treated with heart failure medication alone (8.3% vs. 13.2%, respectively). We thank the FDA for its speedy review and approval of the important follow-on Phase III trial.

Heart Failure 105

Heart Failure Biomarkers Reimbursement CMS 105

DAIC

JANUARY 27, 2025

13, 2025 Medtronic recentlyannounced that the Centers for Medicare & Medicaid Services (CMS) is opening a national coverage analysis (NCA) on renal denervation, a process that will allow the agency to review and develop a national Medicare coverage policy for renal denervation procedures for patients with hypertension. Available at: [link].

CMS 52

CMS Blood Pressure Medicare Hypertension 52